Isoquercetin in Sickle Cell Anemia

NCT ID: NCT04474626

Last Updated: 2021-01-11

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-31
• Study Completion Date: 2024-12-31

Brief Summary

This research study is being done to assess the safety and effectiveness of isoquercetin to reduce levels of soluble P-Selectin in patients with sickle cell disease. Isoquercetin is a naturally occurring flavonoid-or vitamin. You will find quercetin and isoquercetin in fruits and vegetables.

The names of the study drug involved in this study are/is:

• Isoquercetin

Detailed Description

This is a single-arm phase 2 study in adults with Sickle Cell Disease (SCD) to assess the effect of oral isoquercetin on biomarkers of endothelial and platelet activation, inflammation and ongoing blood coagulation.

• The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

• The names of the study drug involved in this study are/is: Isoquercetin
• Participants will receive study treatment for 1 year and will be followed for 30 days after the last dose.
• This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
• The U.S. Food and Drug Administration (FDA) has not approved isoquercetin as a treatment for any disease.

Conditions

Sickle Cell Disease; Sickle Cell-Beta0-Thalassemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ISOQUERCETIN

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits

• ISOQUERCETIN: Oral Study Drug, 1 time per day, per predetermined dosed per 28 treatment cycle.

This will continue for up to 337 days.

Group Type: EXPERIMENTAL

Isoquercetin

Intervention Type: DRUG

Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.

Interventions

Isoquercetin

Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.

Intervention Type: DRUG

Other Intervention Names

IQC-950AN

Eligibility Criteria

Inclusion Criteria

• Eligible subjects require an established diagnosis of sickle cell disease/homozygous hemoglobin S (SCD-SS) or sickle cell disease hemoglobin β0-thalassemia (SCD-Sβ0-thal).
• Patients on other therapy including hydroxyurea will be included.
• Age 18-50 years.
• Participants must have preserved organ and marrow function as defined below:

• leukocytes ≥2,000/mcL
• platelets ≥75,000/mcL
• AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
• Estimated creatinine clearance ≥45 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
• Subjects with no evidence of worsening over the last 4 weeks (e.g. any acute complication of SCD including but not limited to VOC, acute chest syndrome and stroke, that required unscheduled medical attention or intervention) as determined by the investigator will be included.
• Patients on anticoagulation therapy will be excluded.
• The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of isoquercetin administration.
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Participants may not be concurrently receiving any other study agents.
• Subjects with no evidence of worsening over the last 1 month (e.g. any acute complication of SCD including but not limited to VOC, acute chest syndrome and stroke, that required unscheduled medical attention or intervention) as determined by the investigator will be included.
• Familial bleeding diathesis.
• Known diagnosis of disseminated intravascular coagulation.
• Currently receiving anticoagulant therapy.
• Currently using daily use of aspirin (>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days)
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to isoquercetin.
• Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness/social situations that would limit study compliance.
• Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin. These potential risks may also apply to other agents used in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Quercegen Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Jeffrey Zwicker, MD

OTHER

Sponsor Role: lead

Responsible Party

Jeffrey Zwicker, MD

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jeffrey Zwicker, MD

Role: PRINCIPAL_INVESTIGATOR

Beth Israel Deaconess Medical Center

Other Identifiers

20-087

Identifier Type: -

Identifier Source: org_study_id